May 18, 2020
First Subjects Dosed in Australian Phase I Clinical Study of a Denosumab Biosimilar
Feb 04, 2020
Frost & Sullivan Releases Osteoporosis Drug Market Data
Dec 12, 2019
European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Apr 09, 2019
FDA Approves EVENITY(TM) (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Jan 16, 2019
Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY(TM) (romosozumab)
Jan 08, 2019
EVENITY(TM) (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture
Oct 31, 2018
Study: Denosumab Effective in Treating Osteoporosis in Transfusion-Dependent Thalassemia
Jul 25, 2018
Innovent Receives IND Approval to Initiate Clinical Trials in China with its anti-OX40 Agonistic Antibody IBI101 and its anti-RANKL Antibody IBI307
Jul 13, 2018
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
Jun 08, 2018
European Commission Approves Prolia® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
May 21, 2018
FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis
Apr 27, 2018
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Apr 03, 2018
European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Feb 23, 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Jan 08, 2018
NeuClone Discloses Details of its Fifth Product: A Biosimilar Candidate for Prolia/XGEVA (Denosumab)
Jan 08, 2018
European Medicines Agency Accepts Filing For EVENITY(TM) (Romosozumab)
Jan 05, 2018
FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Oct 09, 2017
FDA Accepts Supplemental Biologics License Application For Prolia® (Denosumab) In Glucocorticoid-Induced Osteoporosis
Sep 08, 2017
Amgen Highlights The Latest EVENITY(TM) (Romosozumab) And Prolia® (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting
Jul 31, 2017
Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis